Author:
Kerstjens Huib A M,Gosens Reinoud
Subject
Pulmonary and Respiratory Medicine
Reference10 articles.
1. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials;Brighling;Lancet Respir Med,2020
2. Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation;Bain;J Pharmacol Exp Ther,2011
3. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids;Bateman;Eur Respir J,2017
4. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma;Erpenbeck;Pulm Pharmacol Ther,2016
5. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial;Gonem;Lancet Respir Med,2016
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献